143 related articles for article (PubMed ID: 8281619)
1. Combined oral administration of etoposide and arabinofuranosylcytosine-5'-stearylphosphate enhances the antitumor effect against P388 ascites tumors.
Higashigawa M; Cao DC; Matsui K; Yamada S; Kakitou H; Kagawa Y; Inamochi H; Ido M; Sakurai M
Cancer Chemother Pharmacol; 1994; 33(4):281-5. PubMed ID: 8281619
[TBL] [Abstract][Full Text] [Related]
2. Deoxyribonucleoside triphosphate pools and Ara-CTP levels in P388 murine leukemic cells treated with 1-B-D-arabinofuranosylcytosine-5'-stearylphosphate which is a newly synthesized derivative of 1-B-D-arabinofuranosylcytosine.
Higashigawa M; Hori H; Ohkubo T; Kawasaki H; Yoshizumi T; Sakurai M
Med Oncol Tumor Pharmacother; 1990; 7(4):223-6. PubMed ID: 2283889
[TBL] [Abstract][Full Text] [Related]
3. Antitumor activity and pharmacology of 1-beta-D-arabinofuranosylcytosine-5'-stearylphosphate: an orally active derivative of 1-beta-D-arabinofuranosylcytosine.
Kodama K; Morozumi M; Saitoh K; Kuninaka A; Yoshino H; Saneyoshi M
Jpn J Cancer Res; 1989 Jul; 80(7):679-85. PubMed ID: 2507491
[TBL] [Abstract][Full Text] [Related]
4. 1-beta-D-arabinofuranosylcytosine conjugates of thioether phospholipids as a new class of potential antitumor drugs.
Hong CI; Kirisits AJ; Buchheit DJ; Nechaev A; West CR
Cancer Drug Deliv; 1986; 3(2):101-13. PubMed ID: 3708534
[TBL] [Abstract][Full Text] [Related]
5. Clinical pharmacology of 1-beta-D-arabinofuranosylcytosine-5'-stearylphosphate, an orally administered long-acting derivative of low-dose 1-beta-D-arabinofuranosylcytosine.
Ueda T; Kamiya K; Urasaki Y; Wataya S; Kawai Y; Tsutani H; Sugiyama M; Nakamura T
Cancer Res; 1994 Jan; 54(1):109-13. PubMed ID: 8261429
[TBL] [Abstract][Full Text] [Related]
6. [Experimental combination chemotherapy of YNK01, a novel analog of cytarabine, with other antitumor agents].
Uchida T; Nagahata T; Arakawa M; Ekimoto H; Takahashi K
Gan To Kagaku Ryoho; 1990 Jul; 17(7):1351-6. PubMed ID: 2114829
[TBL] [Abstract][Full Text] [Related]
7. [Antitumor activity of a novel analog of cytarabine, 4-amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone 5'-(sodium octadecyl phosphate) monohydrate (YNK01)].
Nagahata T; Shibasaki C; Ishii T; Uchida T; Arakawa M; Kusama K; Ekimoto H; Takahashi K
Gan To Kagaku Ryoho; 1990 Aug; 17(8 Pt 1):1437-45. PubMed ID: 2389942
[TBL] [Abstract][Full Text] [Related]
8. Increased sensitivity to 1-beta-D-arabinofuranosylcytosine in P388 murine leukemic cells resistant to etoposide.
Higashigawa M; Ido M; Ohkubo T; Kawasaki H; Kamiya H; Sakurai M; Taniguchi K; Hamazaki M
Leuk Res; 1989; 13(1):39-42. PubMed ID: 2915574
[TBL] [Abstract][Full Text] [Related]
9. [Phase I study of YNK01 (1-beta-D-arabinofuranosylcytosine-5'-stearylphosphate)].
Fukuoka M; Miyazaki T; Yoshida Y; Hattori M; Niitani H; Nakamura T; Hirota Y; Ohta K; Tanaka M; Suzuoki Y
Gan To Kagaku Ryoho; 1990 Nov; 17(11):2213-9. PubMed ID: 2241185
[TBL] [Abstract][Full Text] [Related]
10. [Clinical efficacy of YNK 01 (1-beta-D-arabinofuranosylcytosine-5'-stearylphosphate) in patients with polycythemia vera].
Naito K; Kitaori K; Morishima Y
Gan To Kagaku Ryoho; 1993 May; 20(7):973-6. PubMed ID: 8489306
[No Abstract] [Full Text] [Related]
11. Therapeutic efficacy of combination of antitumor agent with AHC-52 against multidrug-resistant cells in the intravenously inoculated P388 leukemia model.
Shinoda H; Ebisu H; Mitsuhashi J; Inaba M; Tsuruo T
Cancer Chemother Pharmacol; 1992; 30(5):335-40. PubMed ID: 1505070
[TBL] [Abstract][Full Text] [Related]
12. [Treatment of refractory hematologic malignancies by combination of cytarabine ocfosfate and etoposide].
Kiyama Y; Suzuki G; Masauzi N; Ohizumi H; Kobayashi N; Ogasawara M; Naohara T; Saito M; Higa T; Kasai M
Gan To Kagaku Ryoho; 1996 Oct; 23(12):1717-20. PubMed ID: 8886052
[TBL] [Abstract][Full Text] [Related]
13. Enhancement of antitumour activity of etoposide by dihydropyridines on drug-sensitive and drug-resistant leukaemia in mice.
Kiue A; Sano T; Naito A; Okumura M; Kohno K; Kuwano M
Br J Cancer; 1991 Aug; 64(2):221-6. PubMed ID: 1892749
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of Ara-CMP-Stearate (YNK01): phase I study of the oral Ara-C derivative.
Schleyer E; Braess J; Ramsauer B; Unterhalt M; Kaufmann C; Wilde S; Schüssler M; Hiddemann W
Leukemia; 1995 Jun; 9(6):1085-90. PubMed ID: 7596174
[TBL] [Abstract][Full Text] [Related]
15. Decreased DNA polymerase sensitivity to 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in P388 murine leukemic cells resistant to vincristine.
Higashigawa M; Ido M; Nagao Y; Kuwabara H; Hori H; Ohkubo T; Kawasaki H; Sakurai M
Leuk Res; 1991; 15(8):675-81. PubMed ID: 1895749
[TBL] [Abstract][Full Text] [Related]
16. Enhanced incorporation of 1-beta-D-arabinofuranosylcytosine by pretreatment with etoposide.
Ooi K; Ohkubo T; Kuwabara H; Higashigawa M; Kawasaki H; Kakitoh H; Kagawa Y; Inagaki S; Sumida K; Sakurai M
Cancer Invest; 1993; 11(4):388-92. PubMed ID: 8324643
[TBL] [Abstract][Full Text] [Related]
17. 1-beta-D-arabinofuranosylcytosine metabolism and incorporation into DNA as determinants of in vivo murine tumor cell response.
Riva CM; Rustum YM
Cancer Res; 1985 Dec; 45(12 Pt 1):6244-9. PubMed ID: 2998596
[TBL] [Abstract][Full Text] [Related]
18. Chemotherapy with [SP-4-3-(R)]-[1,1-cyclobutanedicarboxylato(2-)](2- methyl-1,4-butanediamine-N,N')platinum (CI-973, NK121) in combination with standard agents against murine tumors in vivo.
Elliott WL; Roberts BJ; Howard CT; Leopold WR
Cancer Res; 1994 Aug; 54(16):4412-8. PubMed ID: 8044790
[TBL] [Abstract][Full Text] [Related]
19. [A case of complete remission from acute unclassified leukemia achieved by using a prodrug of ara C, stearyl-ara-CMP (YNK01)].
Nishikawa M; Morita K; Komada F; Uemura Y; Kageyama S; Minami N; Deguchi K; Shirakawa S
Gan No Rinsho; 1990 Oct; 36(12):2204-9. PubMed ID: 2232191
[TBL] [Abstract][Full Text] [Related]
20. Combination chemotherapy involving orally administered etoposide and JM-216 in murine tumor models.
Rose WC
Cancer Chemother Pharmacol; 1997; 40(1):51-6. PubMed ID: 9137529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
